Gazyva

Active Ingredient(s): Obinutuzumab
FDA Approved: * November 1, 2013
Pharm Company: * GENENTECH
Category: Cancer

Obinutuzumab, sold under the brand name Gazyva among others, is a humanized anti-CD20 monoclonal antibody, originated by GlycArt Biotechnology AG and developed by Roche as a cancer treatment. It can be used as a first-line treatment for chronic lymphocytic leukemia in combination with chemotherapy or with venetoclax, as a first-line treatment for follicular lymphoma in combination with chemotherapy, and as treatment for relapsed or refractory follicular lymphoma in combination with bendamusti... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Gazyva 1000 mg/40ml Intravenous Injection, Solution, Concentrate

NDC: 50242-070

Labeler:

Genentech, Inc.